Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec and Radiation in Soft Tissue Sarcoma
NCT06660810Phase 2Active, not recruiting
- Start
- Mar 2025
- Primary completion
- May 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in soft tissue sarcoma (STS). Primary endpoint: Pathologic Complete Response rate. Started Mar 2025; status: active, not recruiting.
02
Drugs
talimogene laherparepvec
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06660810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660810.